TABLE 4.
Unadjusted Concordance Rates for Each Guideline Measure by Center Type and Evidence Grade
| NCI-Designated Centers |
Other Institutions |
|
|---|---|---|
| Category 1 | ||
| Chemo or med onc eval for stage III colon cancer (age < 80 yrs) |
98% | 97% |
| XRT or rad onc eval for T4N0 or stage III rectal cancer (age < 80 yrs) |
97% | 91% |
| Nodal evaluation for invasive breast cancer ≥ 1 cm |
93% | 92% |
| XRT or rad onc eval for BCS (age < 70 yrs) |
100% | 99% |
| Chemo or med onc eval for ER-negative breast cancer (age < 70 yrs) |
99% | 98% |
| Postmastectomy radiation therapy or rad onc eval for high risk* breast cancer |
99% | 95% |
| Category 2A | ||
| Gastric cancer lymph node examination ≥ 15 nodes |
55% | 30% |
| Colon cancer lymph node examination ≥ 12 nodes |
68% | 48% |
| Axillary dissection for node positive breast cancer |
95% | 97% |
| Total thyroidectomy for papillary thyroid cancer ≥ 1.5 cm |
94% | 89% |
| Central neck dissection for node positive papillary thyroid cancer |
85% | 71% |
*
High risk ≥ 4 positive nodes, tumor size > 5.0 cam and node positive or stage III disease.
Chemo indicates chemotherapy; Med onc eval, medical oncology evaluation; Rad onc eval, radiation oncology evaluation; XRT, radiation therapy.